Cabaletta Bio, Inc.(NASDAQ : CABA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.75%||69.90||1.0%||$468.13m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.83%||622.38||2.7%||$403.41m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.14%||231.40||1.9%||$334.69m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.33%||2.93||0.7%||$204.82m|
|EXAS||EXACT Sciences Corp.||0.07%||77.47||17.9%||$154.26m|
|ARNA||Arena Pharmaceuticals, Inc.||-0.39%||91.62||13.7%||$144.85m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.04%||139.25||8.2%||$139.18m|
|BMRN||BioMarin Pharmaceutical, Inc.||-0.02%||86.69||4.2%||$106.18m|
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.